Fibrinogen concentrate versus placebo for treatment of postpartum haemorrhage: Obstetrics Bleeding Study 2
| ISRCTN | ISRCTN46295339 |
|---|---|
| DOI | https://doi.org/10.1186/ISRCTN46295339 |
| Clinical Trials Information System (CTIS) | 2012-005511-11 |
| Protocol serial number | SPON 1155-12 |
| Sponsor | Cardiff University (UK) |
| Funder | CSL Behring (UK) |
- Submission date
- 04/06/2013
- Registration date
- 01/07/2013
- Last edited
- 24/07/2019
- Recruitment status
- No longer recruiting
- Overall study status
- Completed
- Condition category
- Pregnancy and Childbirth
Plain English summary of protocol
Background and study aims
Bleeding at the time of childbirth (postpartum haemorrhage, PPH) is a major cause of death. Bleeding is caused when the uterus fails to contract or by operations. This is made worse by damage of blood clotting system. A number of studies have shown that low levels of a blood clotting factor called fibrinogen is associated with worse bleeding, the need for surgical measures and the need for blood transfusion (taking blood from one person and giving to other). The aim of this study is to find out whether giving fibrinogen early during bleeding at the time of childbirth reduces blood loss.
Who can participate?
Women experiencing major postpartum haemorrhage (PPH) can participate in this study.
What does the study involve?
Participating women are randomly allocated to one of two groups. One group receives fibrinogen concentrate injected into the vein and the other group receives a placebo (dummy). All participants are contacted via telephone after 6 weeks by a midwife.
What are the possible benefits and risks of participating?
It is hoped that giving fibrinogen will reduce blood loss, so there may be a benefit to the participant from taking part in this study. It is hoped that the results may help to improve the treatment of women who experience similar blood loss at the time of childbirth in the future. Fibrinogen is not a new treatment and it has been used in patients who have low levels of fibrinogen for many years, but its use in bleeding at the time of childbirth is relatively new. There is no evidence to suggest that fibrinogen has any serious side effects when used during childbirth but, because it is not routinely used at this time, we may not know all the possible side effects. The idea of giving women fibrinogen is to thicken the blood to stop bleeding but it is possible that this may cause clots where they are not needed and we will be especially looking for this.
Where is the study run from?
The study will be run from four centres in the UK: Cardiff and Vale University Health Board, Leicester Royal Infirmary, University College Hospital London and Liverpool Women's Hospital NHS Foundation Trust.
When is the study starting and how long is it expected to run for?
June 2013 to September 2014
Who is funding the study?
CSL Behring (UK)
Who is the main contact?
Dr Peter Collins
Peter.collins@wales.nhs.uk
Contact information
Scientific
Dept of Haematology, School of Medicine, Cardiff University
Heath Park
Cardiff
CF14 4XN
United Kingdom
| peter.collins@wales.nhs.uk |
Study information
| Primary study design | Interventional |
|---|---|
| Study design | Prospective randomised double-blind placebo-controlled trial |
| Secondary study design | Randomised controlled trial |
| Study type | Participant information sheet |
| Scientific title | Fibrinogen concentrate versus placebo for treatment of postpartum haemorrhage: a multicentre, prospective, double blind randomised controlled trial |
| Study acronym | OBS2 |
| Study objectives | Infusion of fibrinogen concentrate early during a moderately severe and ongoing postpartum haemorrhage, in women with a reduced fibrinogen, as measured by the FIBTEM A5 test, will reduce the total number of allogeneic blood products (red blood cells, fresh frozen plasma, platelet concentrates and cryoprecipitate) transfused after study medication until discharge. |
| Ethics approval(s) | Scotland A Research Ethics Committee, 26/03/2013, ref: 13/SS/0008 |
| Health condition(s) or problem(s) studied | Reproductive Health & Childbirth |
| Intervention | Participants randomised to receive either a bolus infusion of fibrinogen concentrate or placebo. Fibrinogen concentrate will be supplied as a lyophilised powder in glass bottles each containing 1 gm of fibrinogen. The fibrinogen will be dissolved in 50 mL of sterile water before infusion. The matching placebo will be an equal volume of normal saline. Dose: Between 2 g and 8 g (administered intravenously) depending on the ideal weight for height of the woman and measured Fibtem level. Women who are randomised to receive fibrinogen concentrate or placebo will be contacted by telephone after 6 weeks by a research midwife or other study team member. |
| Intervention type | Other |
| Primary outcome measure(s) |
The total number of allogeneic blood products (red blood cells + fresh frozen plasma (FFP) + cryoprecipitate + platelets) transfused after study medication until discharge, compared to placebo. |
| Key secondary outcome measure(s) |
To explore the effect of fibrinogen concentrate infusion on the following efficacy endpoints: |
| Completion date | 26/11/2015 |
Eligibility
| Participant type(s) | Patient |
|---|---|
| Age group | Adult |
| Lower age limit | 18 Years |
| Sex | Female |
| Target sample size at registration | 1050 |
| Key inclusion criteria | 1. Age 18 years or over 2. Women should have any one of the following within the first 12 hours after delivery: 2.1. Haemorrhage of about 1500 ml and ongoing bleeding without another complication 2.2. Haemorrhage of about 1000 mL and ongoing bleeding with any of: 2.2.1. caesarean section 2.2.2. uterine atony 2.2.3. placental abruption* 2.2.4. placenta praevia 2.2.5. Cardiovascular instability (arterial blood pressure below 90 mm/Hg and heart rate greater than 100 bpm) 2.2.6. Clinical observation of microvascular oozing * If in the event of a placental abruption, women may be recruited if there is less than 1000ml visible blood loss, because bleeding at the time of abruption maybe concealed. 3. Women can be included if they fulfil the inclusion criteria after delivery of the baby but where the bleeding had started in the antenatal period (antepartum haemorrhage) 4. Women can be included where there is a slow accumulation of on-going blood loss (in the first 12 hours after delivery) if they fulfil the inclusion criteria |
| Key exclusion criteria | 1. Women who have documented that they do not want to participate in the study during the antenatal period 2. Women declining infusion of red blood cells or blood components 3. Known inherited bleeding disorder 4. Placenta accreta diagnosed antenatally 5. Women who have already received uterine brace sutures, uterine tamponade balloons, radiology intervention or hysterectomy before entering the study 6. Clinical suspicion of amniotic fluid embolism 7. Secondary postpartum haemorrhage (haemorrhage which starts >12 hours after delivery) |
| Date of first enrolment | 01/06/2013 |
| Date of final enrolment | 30/09/2014 |
Locations
Countries of recruitment
- United Kingdom
- Wales
Study participating centre
CF14 4XN
United Kingdom
Results and Publications
| Individual participant data (IPD) Intention to share | No |
|---|---|
| IPD sharing plan summary | Not provided at time of registration |
| IPD sharing plan |
Study outputs
| Output type | Details | Date created | Date added | Peer reviewed? | Patient-facing? |
|---|---|---|---|---|---|
| Results article | results | 01/09/2017 | Yes | No | |
| Results article | results | 01/09/2017 | Yes | No | |
| Protocol article | protocol | 17/04/2015 | Yes | No | |
| HRA research summary | 28/06/2023 | No | No | ||
| Participant information sheet | Participant information sheet | 11/11/2025 | 11/11/2025 | No | Yes |
Editorial Notes
24/07/2019: The overall trial end date has been changed from 30/09/2014 to 26/11/2015.
04/10/2017: Publication references added.
